5don MSN
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation July 6, 2026 9:30 AM ...
Monday - Friday, 08:00 - 11:00 CET | 14:00 - 17:00 HK/SG Pascal Soriot, CEO of British pharmaceutical giant AstraZeneca, discusses the company's $2.5 billion investment in a new China research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results